Cognitive Enhancement Research Dihexa Dihexa has been directly tested in cognitive paradigms (aged rat water maze, scopolamine reversal) and demonstrates synaptogenesis through HGF/c-Met signaling, providing a more direct cognitive enhancement rationale than PE-22-28 Neurogenesis and Mood Research PE-22-28 PE-22-28 induces hippocampal neurogenesis within 4 days and demonstrates antidepressant-like effects through TREK-1 blockade, making it more relevant for mood-cognition intersection research Oral Bioavailability Requirement Dihexa Dihexa has demonstrated approximately 38% oral bioavailability with BBB penetration, while PE-22-28 oral availability has not been characterized Lower Theoretical Risk Profile PE-22-28 PE-22-28 targets an ion channel without known oncological associations, whereas Dihexa activates the HGF/c-Met pathway which is a characterized oncogenic signaling axis Evidence Reliability PE-22-28 PE-22-28 has no retracted publications in its evidence base, while a key 2014 Dihexa paper was retracted for data fabrication concerns Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Pharmacokinetics: Cagrilintide exhibits favorable pharmacokinetic properties, delivering effective results when administered subcutaneously or intravenously
The FDA can take it or leave it," Tatem noted
CafriGGartnerJJZaksTHopsonKLevinNPariaBCet almRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Nephrol Dial Transplant (2017) 32(8):13229
Lancet 402 , 429431 (2023)
